Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 46 publications
Durable responses to triplet immunotherapy targeting TGF-β, PD-L1, and tumor antigen, with an IL-15 receptor superagonist in mismatch repair proficient castration-resistant prostate cancer.
Journal: Journal for immunotherapy of cancer
Published: July 08, 2026
Phase Ib and dose-expansion study of GSK3326595, a PRMT5 inhibitor as monotherapy and in combination with pembrolizumab in patients with advanced cancers.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: February 26, 2025
Novel Combination Immunotherapy and Clinical Activity in Patients With HPV-Associated Cancers: A Nonrandomized Clinical Trial.
Journal: JAMA oncology
Published: February 20, 2025
Alopecia and hair repigmentation associated with anti-programmed death-ligand 1 (PD-L1) immunotherapy.
Journal: JAAD case reports
Published: January 22, 2025
PRGN-2009 and bintrafusp alfa for patients with advanced or metastatic human papillomavirus-associated cancer.
Journal: Cancer immunology, immunotherapy : CII
Published: October 21, 2024
Prediction of cancer treatment response from histopathology images through imputed transcriptomics.
Journal: Research square
Published: October 04, 2023
Immune correlates with response in patients with metastatic solid tumors treated with a tumor targeting immunocytokine NHS-IL12.
Journal: International immunopharmacology
Published: May 26, 2023
Avelumab in Patients With Metastatic Colorectal Cancer.
Journal: The oncologist
Published: April 19, 2023
First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma.
Journal: Journal for immunotherapy of cancer
Published: March 31, 2023
Last Updated: 09/26/2026